Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products

Translucent human figure with lungs highlighted

CDC, the U.S. Food and Drug Administration (FDA), state and local health departments, and other clinical and public health partners are investigating a national outbreak of e-cigarette, or vaping, product use associated lung injury (EVALI).

calendar alt icon Updated December 6, 2019, at 2:30 PM EST

What is New

CDC has analyzed national data on use of THC-containing product brands by EVALI patients.

  • Overall, 152 different THC-containing product brands were reported by EVALI patients.
  • Dank Vapes, a class of largely counterfeit THC-containing products of unknown origin, was the most commonly reported product brand used by patients nationwide, although there are regional differences. While Dank Vapes was most commonly reported in the Northeast and South, TKO and Smart Cart brands were more commonly reported by patients in the West and Rove was more common in the Midwest.
  • The data further supports that EVALI is associated with THC-containing products and that it is not likely associated with a single THC-containing product brand.

CDC recommends that people should not use THC-containing e-cigarette, or vaping, products, particularly from informal sources like friends, family, or in-person or online dealers. In addition, people should not add any substances to e-cigarette or vaping products that are not intended by the manufacturer, including products purchased through retail establishments.

THC-containing products continue to be the most commonly reported e-cigarettes, or vaping, products used by EVALI patients, and it appears that vitamin E acetate is associated with EVALI. However, many substances and product sources are being investigated, and there might be more than one cause. Therefore, while the investigation continues, persons should consider refraining from the use of all e-cigarette, or vaping, products.

CDC will continue to update guidance, as appropriate, as new data become available from this complex outbreak.

What We Know

Laboratory Findings Reported November 8, 2019:

  • Analyses of bronchoalveolar lavage (BAL) fluid samples (fluid samples collected from the lungs) of patients with e-cigarette, or vaping, product use associated lung injury (EVALI) identified vitamin E acetate, an additive in some THC-containing e-cigarette, or vaping, products.
  • CDC laboratory test results of BAL fluid samples from 29 patients submitted to CDC from 10 states found vitamin E acetate in all of the samples.
    • THC was identified in 82% of the samples and nicotine was identified in 62% of the samples.
    • CDC tested for a range of other chemicals that might be found in e-cigarette, or vaping, products, including plant oils, petroleum distillates like mineral oil, MCT oil, and terpenes (which are compounds found in or added to THC products). None of these chemicals of concern were detected in the BAL fluid samples tested.
  • This is the first time that we have detected a chemical of concern in biologic samples from patients with these lung injuries. These findings provide direct evidence of vitamin E acetate at the primary site of injury within the lungs.
  • These findings complement the ongoing work of FDAexternal icon and some state public health laboratories to characterize e-liquid exposures and inform the ongoing national outbreak.

About the Outbreak:

  • The EVALI cases and EVALI deaths reported as of December 3, 2019, include data from a two-week period, November 17 through November 30.
  • As of December 3, 2019, CDC will only report hospitalized EVALI cases and EVALI deaths regardless of hospitalization status. CDC has removed nonhospitalized cases from previously reported case counts.
    • Due to only reporting hospitalized EVALI cases as of December 3, 2019, CDC removed 175 nonhospitalized cases from previously reported national cases. See Public Health Reporting for more information.
  • As of December 3, 2019, a total of 2,291 hospitalized EVALI cases have been reported to CDC from all 50 states, the District of Columbia, and two U.S. territories (Puerto Rico and U.S. Virgin Islands).
    • Forty-eight deaths have been confirmed in 25 states and the District of Columbia (as of December 3, 2019).
  • Although the number of reported cases appears to be declining, states are still reporting new hospitalized EVALI cases to CDC on a weekly basis and should remain vigilant with EVALI case finding and reporting.

About Patient Exposure:

  • All EVALI patients have reported a history of using e-cigarette, or vaping, products.
    • Vitamin E acetate has been identified as a chemical of concern among people with e-cigarette, or vaping, product use associated lung injury (EVALI).
    • THC is present in most of the samples tested by FDA to date, and most patients report a history of using THC-containing e-cigarette, or vaping, products.
    • The latest national and state findings suggest THC-containing e-cigarette, or vaping, products, particularly from informal sources like friends, family, or in-person or online dealers, are linked to most of the cases and play a major role in the outbreak.
  • CDC has analyzed national data on use of THC-containing product brands by EVALI patients.
    • Overall, 152 different THC-containing product brands were reported by EVALI patients.
    • Dank Vapes, a class of largely counterfeit THC-containing products of unknown origin, was the most commonly reported product brand used by patients nationwide, although there are regional differences. While Dank Vapes was most commonly reported in the Northeast and South, TKO and Smart Cart brands were more commonly reported by patients in the West and Rove was more common in the Midwest.
What We Don't Know
  • While it appears that vitamin E acetate is associated with EVALI, evidence is not yet sufficient to rule out contribution of other chemicals of concern.
    • Many different substances and product sources are still under investigation, and it may be that there is more than one cause of this outbreak.
What CDC Recommends
  • CDC recommends that people do not use THC-containing e-cigarette, or vaping, products.
  • CDC also recommends that people should not:
    • Buy any type of e-cigarette, or vaping, products, particularly those containing THC from informal sources like friends, family, or in-person or online dealers.
    • Modify or add any substances to e-cigarette, or vaping, products that are not intended by the manufacturer, including products purchased through retail establishments.
  • While it appears that vitamin E acetate is associated with EVALI, evidence is not yet sufficient to rule out contribution of other chemicals of concern.
    • Many different substances and product sources are still under investigation, and it may be that there is more than one cause of this outbreak.
  • The only way to assure that you are not at risk while the investigation continues is to consider refraining from use of all e-cigarette, or vaping, products.
  • Adults using e-cigarettes to quit smoking should not go back to smoking; they should weigh all risks and benefits and consider utilizing FDA approved cessation medicationsexternal icon. Contact your healthcare provider if you need help quitting tobacco products, including e-cigarettes.
  • Adults who continue to use an e-cigarette, or vaping, product, should carefully monitor themselves for symptoms and see a healthcare provider immediately if they develop symptoms like those reported in this outbreak.
  • Adults with ongoing problematic marijuana use should seek out evidence-based behavioral treatment. As appropriate, they should also seek treatment for any other co-occurring substance misuse or abuse problems or related health conditions.
  • Regardless of the ongoing investigation:
    • E-cigarette, or vaping, products should never be used by youths, young adults, or women who are pregnant.
    • Adults who do not currently use tobacco products should not start using e-cigarette, or vaping, products. There is no safe tobacco product. All tobacco products, including e-cigarettes, carry a risk.
    • THC use has been associated with a wide range of health effects, particularly with prolonged frequent use. The best way to avoid potentially harmful effects is to not use THC-containing e-cigarette, or vaping, products. Persons with ongoing problematic marijuana use that causes significant impairment or distress should seek evidence-based treatment by a healthcare provider.
  • People who have significant impairment or distress from ongoing problematic use of THC-containing e-cigarette, or vaping, products should seek evidence-based behavioral treatment and recovery services.
Key Facts about Use of E-Cigarette, or Vaping, Products
  • Electronic cigarettes—or e-cigarettes—are also called vapes, e-hookahs, vape pens, tank systems, mods, and electronic nicotine delivery systems (ENDS).
  • Using an e-cigarette is commonly called vaping.
  • E-cigarettes work by heating a liquid to produce an aerosol that users inhale into their lungs.
  • The liquid can contain: nicotine, tetrahydrocannabinol (THC) and cannabinoid (CBD) oils, and other substances and additives. THC is the psychoactive mind-altering compound of marijuana that produces the “high.”
Key Facts about Vitamin E Acetate
  • Vitamin E acetate is used as an additive, most notably as a thickening agent in THC-containing e-cigarette, or vaping, products.
  • Vitamin E is a vitamin found in many foods, including vegetable oils, cereals, meat, fruits, and vegetables. It is also available as a dietary supplement and in many cosmetic products, like skin creams.
  • Vitamin E acetate usually does not cause harm when ingested as a vitamin supplement or applied to the skin. However, previous research suggests that when vitamin E acetate is inhaled, it may interfere with normal lung functioning.

If you have questions about CDC’s investigation into the lung injuries associated with use of e-cigarette, or vaping, products, contact CDC-INFO or call 1-800-232-4636.

Latest Outbreak Information
  • This complex investigation spans almost all states, involves over 2,000 patients, and a wide variety of brands, substances, and e-cigarette, or vaping, products.
  • The EVALI cases and EVALI deaths reported as of December 3, 2019, include data from a two-week period, November 17 through November 30.
  • As of December 3, 2019, CDC will only report hospitalized EVALI cases and EVALI deaths regardless of hospitalization status. CDC has removed nonhospitalized cases from previously reported case counts.
    • Due to only reporting hospitalized EVALI cases as of December 3, 2019, CDC removed 175 nonhospitalized cases from previously reported national case. See Public Health Reporting for more information.
  • As of December 3, 2019, a total of 2,291 cases of hospitalized e-cigarette, or vaping, product use associated lung injury (EVALI) have been reported to CDC from 50 states, the District of Columbia, and two U.S. territories (Puerto Rico and U.S. Virgin Islands).
  • Forty-eight deaths have been confirmed in 25 states and the District of Columbia (as of December 3, 2019):
    • Alabama, California, Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Jersey, New York, Oregon, Pennsylvania, Tennessee, Texas, Utah, and Virginia
    • The median age of deceased patients was 52 years and ranged from 17 through 75 years (as of December 3, 2019).
    • More deaths are under investigation.
  • The persistent decline in number of cases reported each week since mid-September, coupled with the declining percentage of recent cases reported weekly, suggest that the outbreak may have peaked around September 15. However, states continue to report new cases, including deaths, to CDC on a weekly basis.
  • Among cases of hospitalized EVALI patients reported to CDC with available data (as of December 3, 2019):
    • 67% were male (among 2,155 patients with data on sex)
    • 78% were under 35 years old, with a median age of 24 years and age range from 13 to 77 years (among 2,159 patients with data on age)
    • By age group category:
      • 16% of patients were under 18 years old;
      • 38% of patients were 18 to 24 years old;
      • 24% of patients were 25 to 34 years old; and
      • 23% of patients were 35 years or older.
  • 1,782 hospitalized patients had complete information* on substances used in e-cigarette, or vaping, products in the 3 months prior to symptom onset, of whom (as of December 3, 2019):
    • 80% reported using THC-containing products; 35% reported exclusive use of THC-containing products.
    • 54% reported using nicotine-containing products; 13% reported exclusive use of nicotine-containing products.
    • 12% reported using cannabidiol (CBD)-containing products; 1% reported exclusive use of cannabidiol (CBD)-containing products.
    • 40% reported both THC- and nicotine-containing product use.
    • 5% reported no THC-, nicotine-, or CBD-containing product use.
  • Among hospitalized EVALI patients who reported using THC-containing e-cigarette, or vaping product brands:
    • The most commonly reported product brand included Dank vapes (56%), followed by TKO (15%), Smart Cart (13%), and Rove (12%). However, regional difference in THC-containing product use were noted.

* Based on complete reports received.

Number of Lung Injury Cases Reported to CDC as of December 3, 2019

Dates of symptom onset and hospital admission for patients with lung injury associated with e-cigarette use, or vaping — United States, March 31–November 30, 2019
What CDC is Doing

Public Health Response:

  • CDC’s Lung Injury response efforts are committed to:
    • Identify and define the risk factors and the source for lung disease associated with e-cigarette product use, or vaping.
    • Detect and track confirmed and probable cases in the US.
    • Communicate actionable recommendations to state, local, and clinical audiences.
    • Establish lab procedures that can assist with the public heath investigation and patient care.

Partnerships:

  • CDC is working 24/7 to identify the cause or causes of this outbreak.
  • CDC continues to work closely with FDA, states, public health partners, and clinicians on this investigation by providing consultation and technical assistance to states on communication, health alerts, public outreach, and surveillance.
  • CDC has activated the Emergency Operations Center (EOC) to coordinate activities and provide assistance to states, public health partners and clinicians around the nation.
  • CDC worked with states to create case definitions to classify confirmed and probable cases in a consistent way. States are in the process of classifying patients.
    • CDC will report numbers of confirmed and probable lung injury cases once states have finalized their classification of cases.
  • By invitation, CDC has deployed Epidemic Intelligence Service (EIS) officers and other CDC staff to support states.
  • CDC has been communicating with international public health partners. Currently, there is a very small number of similar lung injuries outside the U.S.  and not close to the magnitude in the U.S.

Media and Communication:

  • CDC is maintaining an outbreak webpage with key messages and weekly updates on case counts, deaths, and resources available to healthcare providers, health departments, and the public.
  • CDC is holding congressional briefings, media telebriefings, and regular calls with health departments, clinicians to provide timely updates.

Laboratory Testing:

  • CDC is currently testing bronchoalveolar lavage (BAL) fluid samples as well as blood or urine samples paired to BAL fluid samples.
  • CDC is testing pathologic specimens, including lung biopsy or autopsy specimens, associated with patients.
  • CDC is offering aerosol emission testing of case-associated product samples from e-cigarette, or vaping, products, and e-liquids. For more information about submission, see Product Sample Submission Information.
  • Results can help  provide insight into the nature of chemical exposure(s) contributing to this outbreak.
  • CDC developed guidance documents to assist public health laboratories, healthcare providers, pathologists, and others with specimen collection, storage, and submission to CDC for testing.
  • For more information and resources visit For the Public, For Healthcare Providers and For State and Local Health Departments as well as our Publications and Resources page.